Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1317-1323

  Hoogendijk van Den Akker, Judith M ^a   Harden, Paul N ^c   Hoitsma, Andries J ^a   Proby, Charlotte M ^d   Wolterbeek, Ron ^b   Bavinck, Jan Nico Bouwes ^b   De Fijter, Johan W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL INFECTION; ACNE; ADULT; APHTHOUS STOMATITIS; ARTICLE; CANCER SIZE; CEREBROVASCULAR ACCIDENT; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DYSLIPIDEMIA; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RESPIRATORY TRACT INFECTION; RISK REDUCTION; SEPTICEMIA; SKIN CARCINOMA; SKIN INFECTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

CARCINOMA, SQUAMOUS CELL; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; SIROLIMUS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84876083998     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.6376     Document Type: Article

References (31)

1. Vajdic CM, McDonald SP, McCredie MR, et al: Cancer incidence before and after kidney transplantation. JAMA 296:2823-2831, 2006 (Pubitemid 44969182)
2. Villeneuve PJ, Schaubel DE, Fenton SS, et al: Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 7:941-948, 2007 (Pubitemid 46481211)
3. Wisgerhof HC, van der Geest LG, de Fijter JW, et al: Incidence of cancer in kidney-transplant recipients: A long-term cohort study in a single center. Cancer Epidemiol 35:105-111, 2011
4. Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 348:1681-1691, 2003 (Pubitemid 36459475)
5. Hartevelt MM, Bavinck JN, Kootte AM, et al: Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 49:506-509, 1990 (Pubitemid 20110465)
6. Lindelöf B, Sigurgeirsson B, Gäbel H, et al: Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143:513-519, 2000
7. Ramsay HM, Reece SM, Fryer AA, et al: Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 84:437-439, 2007 (Pubitemid 47258336)
8. Euvrard S, Kanitakis J, Decullier E, et al: Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81:1093-1100, 2006
9. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al: Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: Cumulative incidence and risk factors. Transplantation 89:1231-1238, 2010
10. Harwood CA, Proby CM, McGregor JM, et al: Clinicopathologic features of skin cancer in organ transplant recipients: A retrospective case-control series. J Am Acad Dermatol 54:290-300, 2006 (Pubitemid 43144399)
11. Proby CM, Harwood CA, Neale RE, et al: A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 11:1498-1508, 2011
12. Ramsay HM, Fryer AA, Hawley CM, et al: Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 49:397-406, 2003 (Pubitemid 37051900)
13. Urwin HR, Jones PW, Harden PN, et al: Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 87:1667-1671, 2009
14. Jensen P, Hansen S, Møller B, et al: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177-186, 1999 (Pubitemid 29072794)
15. Otley CC, Cherikh WS, Salasche SJ, et al: Skin cancer in organ transplant recipients: Effect of pretransplant end-organ disease. J Am Acad Dermatol 53:783-790, 2005 (Pubitemid 41501363)
16. Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine induces cancer progression by a cella-utonomous mechanism. Nature 397:530-534, 1999
17. Wu X, Nguyen BC, Dziunycz P, et al: Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 465:368-372, 2010
18. Yarosh DB, Pena AV, Nay SL, et al: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 125:1020-1025, 2005
19. O'Donovan P, Perrett CM, Zhang X, et al: Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871-1874, 2005 (Pubitemid 41325100)
20. Campistol JM, Eris J, Oberbauer R, et al: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17:581-589, 2006
21. Kauffman HM, Cherikh WS, Cheng Y, et al: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883-889, 2005 (Pubitemid 41552882)
22. Schena FP, Pascoe MD, Alberu J, et al: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233-242, 2009
23. Rini BI: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14:1286-1290, 2008
24. Brenneisen P, Sies H, Scharffetter-Kochanek K: Ultraviolet-B irradiation and matrix metalloproteinases: From induction via signaling to initial events. Ann N Y Acad Sci 973:31-43, 2002 (Pubitemid 137597861)
25. Campbell SB, Walker R, Tai SS, et al: Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12:1146-1156, 2012
26. Salgo R, Gossmann J, Schöfer H, et al: Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: Reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 10:1385-1393, 2010
27. Euvrard S, Morelon E, Rostaing L, et al: Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329-339, 2012
28. Weir MR, Mulgaonkar S, Chan L, et al: Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled spare-the-nephron trial. Kidney Int 79:897-907, 2011
29. Alberú J, Pascoe MD, Campistol JM, et al: Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 92:303-310, 2011
30. Saurina A, Campistol JM, Piera C, et al: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21:488-493, 2006 (Pubitemid 43160007)
31. Ojo AO, Held PJ, Port FK, et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931-940, 2003 (Pubitemid 37064766)